Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004072 · ClinicalTrials.gov registry record · Phase 2
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
A Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 3
- Study locations
NCT00004072: Completed Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Case Comprehensive Cancer Center.
NCT00004072 is a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 17 participants, below the 769-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004072, a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining O6-benzylguanine with carmustine in treating patients who have previously untreated, refractory, or relapsing multiple myeloma.
Conditions Studied
Interventions
- DRUG O6-benzylguanine
- DRUG carmustine
Study Locations (3)
Ohio
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center - Cleveland
- MetroHealth Medical Center - Cleveland
Illinois
- University of Chicago Cancer Research Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 1999-09 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
What the finished NCT00004072 record still lists
NCT00004072 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 769-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which O6-benzylguanine is the first listed.
NCT00004072 reports a single indexed study location in Ohio, Illinois.
Frequently Asked Questions
What is clinical trial NCT00004072 about?
NCT00004072 is a clinical study titled "O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining O6-benzylguanine with carmustine in treating patients who h...
What is the current status of trial NCT00004072?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 1999-09. Estimated completion is 2004-09.
What conditions does trial NCT00004072 study?
This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00004072?
The interventions under investigation include: O6-benzylguanine (DRUG), carmustine (DRUG).
Who is sponsoring clinical trial NCT00004072?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004072 being conducted?
This trial has 3 study locations across Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma and Plasma Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00004072's enrollment target sits among peer trials
17 23rd of 26 higher than 4 of 26 other Multiple Myeloma and Plasma Cell Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma and Plasma Cell Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
COMPLETED · Phase 2
-
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
COMPLETED · Phase 2
-
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
COMPLETED · Phase 2
-
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
COMPLETED · Phase 2
-
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
COMPLETED · Phase 2
-
Campath-1H + FK506 and Methylprednisolone for GVHD
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia